Drug

Northland Biotech's Sedominji Completes First National Shipment – World's First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces
Market launchNorthland Biotechnology

Northland Biotech’s Sedominji Completes First National Shipment – World’s First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces

Beijing Northland Biotechnology Co., Ltd. announced that its independently developed Class 1 innovative gene therapy, Sedominji Injection (brand name: Huasuoling®), completed its first nationwide shipment at the production base of…

GeneScience's GenSci161 Wins NMPA Acceptance for Recurrent Pericarditis Clinical Trial – Novel Fully Human IL‑1α/IL‑1β Bispecific Antibody

GeneScience’s GenSci161 Wins NMPA Acceptance for Recurrent Pericarditis Clinical Trial – Novel Fully Human IL‑1α/IL‑1β Bispecific Antibody

Youcare Pharmaceutical's YKYY036 Wins Dual Clinical Clearances from NMPA and FDA – GalNAc‑Conjugated siRNA Targeting INHBE Advances Global Obesity Program

Youcare Pharmaceutical’s YKYY036 Wins Dual Clinical Clearances from NMPA and FDA – GalNAc‑Conjugated siRNA Targeting INHBE Advances Global Obesity Program

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA
Auto-immuneEli Lilly

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

BiosimilarsHenlius Biotech

Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer

Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis
Auto-immuneMarket approval filings

Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis

Dupixent Wins CHMP Positive Opinion for Pediatric CSU – EU Approval Nears for Children Aged 2–11 Years
NASDAQ: SNYSanofi

Dupixent Wins CHMP Positive Opinion for Pediatric CSU – EU Approval Nears for Children Aged 2–11 Years

Show More